Literature DB >> 30602303

KLF11 (Krüppel-Like Factor 11) Inhibits Arterial Thrombosis via Suppression of Tissue Factor in the Vascular Wall.

Wenying Liang1, Yanbo Fan1, Haocheng Lu1, Ziyi Chang1, Wenting Hu1, Jinjian Sun1, Huilun Wang1, Tianqing Zhu1, Jintao Wang1, Reheman Adili2, Minerva T Garcia-Barrio1, Michael Holinstat2, Daniel Eitzman1, Jifeng Zhang1, Y Eugene Chen1.   

Abstract

Objective- Mutations in Krüppel like factor-11 ( KLF11), a gene also known as maturity-onset diabetes mellitus of the young type 7, contribute to the development of diabetes mellitus. KLF11 has anti-inflammatory effects in endothelial cells and beneficial effects on stroke. However, the function of KLF11 in the cardiovascular system is not fully unraveled. In this study, we investigated the role of KLF11 in vascular smooth muscle cell biology and arterial thrombosis. Approach and Results- Using a ferric chloride-induced thrombosis model, we found that the occlusion time was significantly reduced in conventional Klf11 knockout mice, whereas bone marrow transplantation could not rescue this phenotype, suggesting that vascular KLF11 is critical for inhibition of arterial thrombosis. We further demonstrated that vascular smooth muscle cell-specific Klf11 knockout mice also exhibited significantly reduced occlusion time. The expression of tissue factor (encoded by the F3 gene), a main initiator of the coagulation cascade, was increased in the artery of Klf11 knockout mice, as determined by real-time quantitative polymerase chain reaction and immunofluorescence. Furthermore, vascular smooth muscle cells isolated from Klf11 knockout mouse aortas showed increased tissue factor expression, which was rescued by KLF11 overexpression. In human aortic smooth muscle cells, small interfering RNA-mediated knockdown of KLF11 increased tissue factor expression. Consistent results were observed on adenovirus-mediated overexpression of KLF11. Mechanistically, KLF11 downregulates F3 at the transcriptional level as determined by reporter and chromatin immunoprecipitation assays. Conclusions- Our data demonstrate that KLF11 is a novel transcriptional suppressor of F3 in vascular smooth muscle cells, constituting a potential molecular target for inhibition of arterial thrombosis.

Entities:  

Keywords:  Krüppel-like factors; diabetes mellitus; gene; thrombosis; tissue factor; vascular disease

Mesh:

Substances:

Year:  2019        PMID: 30602303      PMCID: PMC6393209          DOI: 10.1161/ATVBAHA.118.311612

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  7 in total

Review 1.  Recent Insights Into the Regulation of Coagulation and Thrombosis.

Authors:  Xian Li; Martha M S Sim; Jeremy P Wood
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-04-22       Impact factor: 8.311

2.  Endothelial KLF11 as a Nephroprotectant in AKI.

Authors:  Gelare Ghajar-Rahimi; Anupam Agarwal
Journal:  Kidney360       Date:  2022-08-25

Review 3.  Krüppel-like factors in glycolipid metabolic diseases.

Authors:  Yutong Li; Xiaotong Zhao; Murong Xu; Mingwei Chen
Journal:  Mol Biol Rep       Date:  2022-05-18       Impact factor: 2.742

4.  Endothelium-targeted overexpression of Krüppel-like factor 11 protects the blood-brain barrier function after ischemic brain injury.

Authors:  Xuejing Zhang; Xuelian Tang; Feifei Ma; Yanbo Fan; Ping Sun; Tianqing Zhu; Jifeng Zhang; Milton H Hamblin; Y Eugene Chen; Ke-Jie Yin
Journal:  Brain Pathol       Date:  2020-04-14       Impact factor: 6.508

5.  KLF11 protects against abdominal aortic aneurysm through inhibition of endothelial cell dysfunction.

Authors:  Guizhen Zhao; Ziyi Chang; Yang Zhao; Yanhong Guo; Haocheng Lu; Wenying Liang; Oren Rom; Huilun Wang; Jinjian Sun; Tianqing Zhu; Yanbo Fan; Lin Chang; Bo Yang; Minerva T Garcia-Barrio; Y Eugene Chen; Jifeng Zhang
Journal:  JCI Insight       Date:  2021-03-08

6.  KLF11 deficiency enhances chemokine generation and fibrosis in murine unilateral ureteral obstruction.

Authors:  Silvana B De Lorenzo; Alyssa M Vrieze; Ruth A Johnson; Karen R Lien; Karl A Nath; Vesna D Garovic; Khashayarsha Khazaie; Joseph P Grande
Journal:  PLoS One       Date:  2022-04-12       Impact factor: 3.240

7.  Therapeutic potential of the Proprotein Convertase Subtilisin/Kexin family in vascular disease.

Authors:  Bianca E Suur; Melody Chemaly; Moritz Lindquist Liljeqvist; Djordje Djordjevic; Markus Stenemo; Otto Bergman; Eva Karlöf; Mariette Lengquist; Jacob Odeberg; Eva Hurt-Camejo; Per Eriksson; Daniel F J Ketelhuth; Joy Roy; Ulf Hedin; Michael Nyberg; Ljubica Matic
Journal:  Front Pharmacol       Date:  2022-09-15       Impact factor: 5.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.